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Introduction: Multidrug-resistant tuberculosis treatment is effective in 50% of 
patients, due to several factors including the antibiotic susceptibility of the 
microorganism, adverse treatment reactions, social factors, and associated 
comorbidities. 
Objectives: Here we describe the demographics, clinical characteristics, and 
factors associated with treatment outcomes in multidrug-resistant tuberculosis 
(MDR-TB) patients in Medellín, Colombia.  
Materials and methods: A retrospective analysis was performed of data from 
patients diagnosed with MDR-TB attending Hospital La María in Medellin-
Colombia, who were treated between 2010-2015. Patients were categorized as 
having a successful (cured) or poor (failure, lost to follow-up, and death) treatment 
outcome. Associations between demographic, clinical factors, laboratory results, 
treatment outcomes, and follow-up information were evaluated by univariate, 
multivariate and multiple correspondence analyses (MCA). 
Results: 128 patients with MDR-TB, 77 (60%) had successful outcomes. Of those 
with poor outcomes, 26 were lost to follow-up, 15 died, and 10 were treatment 
failures. Irregular treatment, the presence of comorbidities, and positive cultures 
beyond >2 months of treatment were associated with poor outcomes compared to 
successful outcomes (p<0.05 for all). MCA grouped patients lost to follow-up with 
HIV and drug addiction, and patients with treatment failure with irregular treatment 
and chronic obstructive pulmonary disease.  
Conclusion: the recognition of factors affecting treatment outcomes is essential 
and was associated with treatment outcomes in this series of patients. Early 
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identification of these factors should increase the rates of treatment success and 
contribute to MDR-TB control. 
Keywords: Tuberculosis, multidrug-resistant; extensively drug-resistant 
tuberculosis; treatment outcome. 
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Introducción. El tratamiento de la tuberculosis multi-fármaco resistente tiene una 
efectividad del 50%, asociado con múltiples factores como la susceptibilidad del 
microorganismo, las reacciones adversas, los factores sociales y las 
comorbilidades. 
Objetivo. Describir la demografía, las características clínicas y los factores 
pronósticos asociados con el desenlace de tratamiento en pacientes multi-
fármacoresistente (TB-MDR) en Medellín, Colombia. 
Materiales y métodos. Se realizó un análisis retrospectivo de los datos de 
pacientes con TB-MDR atendidos en el Hospital La María de Medellín, Colombia 
que fueron tratados entre 2010 y 2015. Los pacientes se categorizaron con 
tratamiento exitoso (curados) o con tratamiento fallido (falla en el tratamiento, 
perdida durante seguimiento y muerte). Se determinó la asociación entre 
características demográficas y clínicas, resultados de laboratorio, desenlaces en el 
tratamiento e información de seguimiento utilizando análisis univariado, 
multivariado y de correspondencia múltiple (ACM). 
Resultados. De 128 pacientes con TB-MDR, 77 (60%) tuvieron un tratamiento 
exitoso. De los que tuvieron un tratamiento fallido, 26 pacientes se perdieron en el 
seguimiento, 15 murieron y 10 tuvieron falla en el tratamiento. Tratamiento 
irregular, comorbilidades y cultivos positivos más allá de 2 meses de tratamiento 
se asociaron significativamente con tratamientos fallidos (p<0.05). ACM agrupó los 
pacientes con pérdida en el seguimiento, con VIH y tratamientos irregulares. Los 
pacientes con tratamientos irregulares y enfermedad pulmonar obstructiva crónica 
con falla en el tratamiento y muerte. 
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Conclusión. El reconocimiento temprano de factores que afectan el desenlace de 
tratamiento en pacientes con TB-MDR es esencial, la identificación de esos 
factores debe incrementar el éxito del tratamiento y contribuir al adecuado control 
de la TB-MDR. 
Palabras clave: tuberculosis resistente a múltiples medicamentos; tuberculosis 
extensivamente resistente a drogas; resultado del tratamiento. 
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Multidrug-resistant tuberculosis (MDR-TB) continues to be an obstacle to disease 
control. It has been estimated that, globally, 4.1% of new TB cases and 19% of 
previously treated cases have MDR-TB. In other words, there are 490.000 new 
MDR-TB cases worldwide. Also, 6.2% of MDR-TB cases are extensively drug-
resistant (XDR) (1). 
Colombia with a population of 45.5 million, reported 13.870 TB cases in 2017, 420 
cases were reported as drug-resistant, 108 as MDR-TB, of them 2.4% were new 
cases and 14% were previously treated (2). According to the national TB program, 
32 XDR-TB cases have been diagnosed in the country to date (3). The Department 
of Antioquia reported a fifth of the national MDR-TB cases and half of these cases 
were reported in Medellin; the capital city (4).  
MDR-TB cases pose problems for TB control programs: expensive treatment, 
longer duration of treatment and lesser efficacy. Also, this treatment is associated 
with more adverse effects than the one required for a regular TB patient. Adverse 
effects, in turn, are accompanied by drug availability constraints, lack of treatment 
compliance, and administrative barriers for delivering and treatment follow-up (5). 
In this context, the global treatment cure rate for MDR-TB is 54%, which is mostly 
affected by mortality and lack of follow up. For XDR-TB, only 30% of patients 
completed successful treatment in the 2014 cohort reported from 138 countries (1). 
From 2000 onwards, the World Health Organization (WHO) and the Stop TB 
Partnership provided support to countries for MDR-TB management through the 
Green Light Committee (GLC). This initiative was created to evaluate, lend 
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guidance, and facilitate access of TB control programs to second-line drugs at 
reduced price with an assured quality  (5). 
In Colombia, a program for MDR-TB treatment was initiated to improve the 
management of these patients with second-line antituberculosis drugs. It was 
supported by GLC and the national TB program (a public-private alliance formed 
by Dirección Seccional de Salud, Secretaría de Salud de Medellin, Hospital La 
María, Corporación para Investigaciones Biológicas, Liga Antituberculosa de 
Antioquia, and Fundación Red de Apoyo Social RASA). This program was located 
in Medellin and started in 2010. In this study, we describe the demographics, 
clinical characteristics, and prognostic factors associated with treatment outcomes 
in these MDR-TB patients. Due to the lack of published studies on treatment 
results of patients with MDR-TB in the country, this study describes a cohort of 
patients treated for MDR-TB and analyze the socio-demographic factors 
associated with their outcomes.  
Materials and methods 
A descriptive retrospective study was done based on data on diagnosis, treatment, 
and outcomes of MDR-TB patients enrolled in a national program for improving 
MDR-TB treatment and management. It included 146 patients diagnosed with 
MDR-TB at Hospital La María in Medellin, who started and received treatment from 
November 2010 to June 2015. Data from 128 patients were finally included in the 
analysis, their final treatment outcome defined as follows:  patients with a 
successful treatment were those cured by microbiological and clinical parameters, 
and patients with a poor treatment outcome included those who failed treatment, 
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those who died (associated with TB condition) and those that were lost to follow-up 
(6). 
Patients included in the program were previously diagnosed with MDR-TB using a 
molecular test GenoType MTBDRplus (Hain Life science GmbH, Nehren, 
Germany) at the Regional Public Health Laboratory. After diagnosis and before 
starting treatment, a new sputum sample was processed using a decontamination 
procedure standard method (7). From the digested sputum a direct smear was 
stained with auramine-rhodamine, in addition, 0.1 mL and 0.5 mL were inoculated 
in Löwenstein-Jensen medium (L-J) and in a mycobacterial growth indicator tube 
(MGIT) respectively (Becton, Dickinson, and Company, Sparks, MD, USA). In 
cultures identified as positive, a smear stained by Kinyoun was performed and 
subcultured on thin layer agar (TLA). Final identification of Mycobacterium 
tuberculosis (MTB) was based on inhibition of MTB complex growth by p-
nitrobenzoic acid in TLA and a standard phenotypic test; resistance to isoniazid 
and rifampin was also confirmed using TLA (8). 
Seventy-nine MDR-TB isolates were tested for susceptibility to second-line drugs 
using the BD Bactec MGIT 960 system (9). Drug stock concentrations were 
prepared following standard recommendations (10,11). Patients were started on 
standard treatment (12), with kanamycin, levofloxacin, cycloserine, pyrazinamide, 
and ethionamide, for 18 to 24 months. A clinical and laboratory follow-up was done 
monthly, as well as an audiometry test at three months and at the end of the 
administration of injectable medication, thorax PA and lateral X-ray were performed 
every six months. Changes in treatment were done due to drug intolerance, drug 
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resistance or the presence of serious adverse effects. Alternative drugs used were 
p-aminosalicylic acid, ethambutol, moxifloxacin, amoxicillin-clavulanate, and 
linezolid.  
Demographic characteristics, clinical results, laboratory results, treatment 
outcomes, and follow-up information were collected from each patient´s clinical 
record. A data collection form was used to extract data from medical records. All 
data were  entered into a Microsoft Excel database. To identify differences in 
means, Student´s t-test or Mann-Whitney U test was used. Odds Ratio (OR), and 
their 95% confidence intervals (CI) were calculated. A p-value of less than 0.05 
defined significant differences. Variables with a p < 0.05 were used in a logistic 
regression model to adjust independent factors associated with treatment outcome. 
We performed a multiple correspondence analysis (MCA) to evaluate the 
relationships among treatment outcomes and patient’s baseline conditions; human 
immunodeficiency virus (HIV) infection, drug addiction, irregular treatment (as 
evidenced by failing to finish treatment or intermittent treatment without completion 
of a full treatment scheme), Chronic obstructive pulmonary disease (COPD), 
diabetes mellitus (DM) and undernourishment. This analysis considers the level of 
significance (weight) of each factor, to explain total sample variability (inertia). All 
analyses were performed using EPIDAT 3.1 and STATA 11.0. 
The study was done under national public health law as part of a pilot program for 
MDR-TB treatment supported by GLC and the national TB program, as such no 
additional ethical approval was necessary. Individual participants gave written 
informed consent before starting treatment according to country regulations, and 
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institutional consent was obtained for record review. All patient information was 
anonymized before analysis.  
Results 
Data from 128 patients treated for MDR-TB and with a treatment outcome were 
analyzed. The patients had a mean age of 40 years, and 69% (n = 88) were male. 
Among the 128 patients, 51 (40%) had an irregular treatment for MDR-TB (41 with 
poor adherence, seven due to problems in drug supply and three with booth 
causes concomitantly) and 112 (88%) had risk factors for MDR before being 
treated for MDR-TB; of these patients, 49 (44%) received irregular previous anti-
tuberculosis treatment, 46 (41%) regular previous anti-tuberculosis treatment, and 
17 (15%) had contact with a TB patient. A variety of adverse effects were found in 
these patients; more common were diarrhea (three patients), vomitus (4 patients), 
hypoacusis (13 patients), and gastritis (15 patients).  Thoracic surgery was 
performed in eight patients (6%), and six of them had a successful outcome. The 
type of surgery practiced was upper lobectomy in four patients, upper bilobectomy 
in one, and pneumonectomy in three. Forty-eight percent of patients had an 
associated comorbidity: drug addiction  (n = 18; 14%), DM (n = 16; 13%), HIV co-
infection (n = 14; 11%), COPD or undernourished (n = 10; 8% each), and other 
comorbidities (n = 16; 13%). A total of 77 (60%) MDR-TB patients had successful 
treatment outcomes, 26 (20%) were lost to follow-up, 15 (12%) died, and 10 (8%) 
had a failure during treatment (table 1 and figure 1). 
In the univariate analysis, irregular treatment and presence of comorbidities had a 
significant association with poor outcome (OR: 5.14; p<0.001 and 4.05; p<0.001, 
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respectively), as well as drug addiction and HIV infection (OR: 4.92; p=0.005 and 
4.45; p=0.017, respectively). Patients with poor outcome took more than two 
months to achieve microbiological sterilization (OR: 1.26; p<0.026) (table 2). Sixty-
five patients (85%) with a successful outcome had negative cultures at two months 
in contrast with 30 patients (60%) with poor outcomes (p= 0.0015). In particular, 
the subgroup of patients with DM needed more than two months for negative 
culture conversion compared with those who did not have DM (p=0.028). Nine 
patients with DM had a successful outcome, and seven had poor outcomes; of 
these seven patients, four patients died, two had treatment failure, and one was 
lost to follow-up.  
Using a forward selection stepwise logistic regression model, we identified two 
factors associated with poor outcome: previous irregular treatment (OR: 9.38, 95% 
CI: 2.30-38.2, p=0.002) and time (months) of positive culture after treatment 
initiation (OR: 1.85, 95% CI: 1.29-2,64, p=0.001). Time of TB treatment for 18 
months was associated with a successful outcome (OR: 0.79, 95% CI: 0.73-0.85, 
p=0.001) (table 2). 
Out of 128 patients, 79 (62%) had a susceptibility test for second-line drugs. Of 
these, 9 (11%) showed resistance exclusively to isoniazid and rifampicin. Seventy 
patients (89%) showed additional resistance to one or more second-line drugs, 54 
(68%) were resistant to ethionamide, 49 (62%) were resistant to pyrazinamide, and 
12 (15%) were resistant to both drugs concomitantly. We found a pre-XDR-TB 
condition in 12 (15%) patients, and five patients had developed XDR-TB; four of 
them died including one diabetic patient who had XDR-TB since his admission. All 
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XDR-TB patients had a positive culture at the time of death or loss to follow-up. 
Seventy-seven patients completed successful treatment; 68 of them received 
cycloserine, 60 received levofloxacin, and 53 patients received kanamycin. Due to 
resistance to ethionamide or to pyrazinamide, or cycloserine adverse effects, 
scheme changes were necessary; 13 patients received linezolid, 41 
amoxicillin/clavulanate, and 2 XDR-TB patients received imipenem. 
Four groups were identified using the MCA analysis (Figure 2). The first group (a) 
comprised patients that were lost to follow up; these patients’ associated baseline 
conditions were HIV infection and drug addiction. The second group (b) included 
patients that died or presented a treatment failure; this group showed an 
association with irregular previous treatment and COPD. The third group (c) 
comprised patients with diabetes and undernourished; those patients were not 
directly associated with any of the outcome categories defined in this study. Finally, 
the fourth group (d) contained patients with a successful outcome; this group was 
not associated with any baseline conditions analyzed in this study (Figure 2). 
Discussion 
In this study, 60% of 128 MDR-TB patients had a successful outcome. Overall, 
treatment outcomes for this population are consistent with previously reported 
outcomes. In a systematic review of 26 trials with a total of 4959 MDR-TB patients, 
62% of patients met the definition of successful treatment (13). The 60% treatment 
success rate for our population was higher than the 54% reported worldwide by 
WHO (1), but it is less than 86% success rate achieved by individualized MDR-TB 
treatment published by Bolhuis et al. (14). In the present study, 26 (20%) patients 
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were lost to follow-up, and seven of these re-initiated their treatment until 
completion. WHO reported a global rate for lost to follow-up of 15% (1). The MCA 
analysis in the present study showed that loss to follow-up is a poor treatment 
outcome associated with HIV infection and drug addiction. One study in Africa 
reported that 56% of HIV patients were lost to follow-up during MDR-TB treatment, 
suggesting that better patient tracking activities,  an improved understanding of the 
reasons that generate loss to follow-up outcomes and an earlier initiation of 
antiretroviral therapy are needed to improve treatment completion (15). In Georgia, 
drug addiction was reported to be significantly associated with a higher risk of loss 
to follow-up (16). For our study, the non-inclusion of patients lost to follow-up in the 
analysis would increase the success of the treatment rate from 60% (77/128) to 
75% (77/102). MCA analysis also identified poor treatment outcomes associated 
with COPD and previous irregular treatment. Several studies have associated 
COPD (17) and previous treatment as independent predictors of death in MDR-TB 
patients (18) or poor treatment outcomes (19). 
Surgery has been recommended for the treatment of patients with MDR-TB who do 
not respond to drug treatment, and have a persistent cavitary well-localized lesion, 
an adequate respiratory function, and when not enough active drugs are available 
to design a curative scheme (20). In our study, eight patients underwent lung 
resection surgery, and six of them had successful outcomes. A systematic review 
and meta-analysis done with data from 24 studies revealed a significant 
association between surgical intervention and successful treatment compared to 
non-surgical intervention (OR 2.24, 95%CI 1.68–2.97) (21). 
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Sputum smear and culture are direct indicators of bacteriological load, the patient’s 
infectious status, and ultimately the success of treatment. Conversion of initial 
sputum culture in the first three months is essential to label the patient as non-
infectious, which in turn is an important indicator to determine whether or not it is 
necessary to extend the time of treatment (22). In this study, most patients with a 
successful outcome (85%) had a sputum culture negative conversion at two 
months, while 60% of patients with a poorer outcome had negative cultures in the 
same period of time. This is consistent with studies in which sputum culture 
conversion within two months was considered as a marker of a successful 
outcome in HIV negative patients (23). In our study, patients with DM needed more 
than two months for negative culture conversion compared with those who did not 
have DM (p=0,028). This finding suggests that in addition to optimal control of DM, 
it would be necessary to extend the recommended duration of treatment in order to 
avoid treatment failure, relapses, and deaths. This situation should be addressed 
when considering the use of a new standardized shorter treatment regimen for 
patients with MDR-TB (24). 
Despite effective anti-tuberculosis chemotherapy, case-fatality rates up to 25% 
have been described in patients with MDR-TB in both industrialized and resource-
poor settings (25). In our study, 16% of MDR-TB patients died, and four of these 
patients had XDR-TB. The cause of the increased death risk in patients with MDR-
TB is diverse, commonly associated with HIV infection, DM, and particular lifestyles 
including alcohol abuse, smoking, and illicit drugs use (25). Among 20 patients in 
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our study who died while on anti-tuberculosis treatment, 17 had comorbidities, 
mainly HIV, DM, and illicit drugs use. 
A common characteristic of isolates from patients in our study was the increased 
resistance to pyrazinamide (62%) and ethionamide (68%). A systematic review and 
meta-analysis found that 61% of patients with confirmed MDR-TB have 
pyrazinamide resistance (26). Ethionamide resistance was found in 13% to 87% of 
MDR-TB patients according to the world region (27,28). Other studies in Medellin 
reported that 33% of MDR isolates have cross-resistance between isoniazid and 
ethionamide, suggesting the need to confirm the susceptibility to ETH and PZA 
before considering their use in the treatment of MDR-TB patients (29). In this 
study, 8% of MDR-TB isolates became XDR during treatment or were XDR-TB at 
the beginning of it. These patients had high mortality (66%), which is similar to that 
reported in other studies, and were associated with DM, malnutrition, and drug 
addiction (30). 
We could not assess a clear relationship between the MDR-TB treatment scheme 
and its outcome due to the variability of schemes used prompted by drugs 
availability, adverse reactions, and initial drug resistance which is a limitation of the 
study. Despite a moderate treatment success obtained in this cohort, a flaw to 
integrate medical, nutritionist, psychologist, and social work care, needed for the 
integral management of patients, was observed. Nevertheless, this program served 
the purpose of increasing the availability of second-line drugs needed for the 
proper management of MDR-TB patients. 
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In conclusion, early recognition of factors that can influence the treatment 
outcomes is essential for the successful treatment of patients with MDR-TB. 
Knowing these factors will help to focus on the care of these patients and should 
become a high priority in a TB program. The interdisciplinary attention to the 
patient, besides an expert medical management and the support of an experienced 
laboratory, should take care of nutritional patient status, comorbid conditions, and 
social and psychological factors that affect the final success of treatment. In the 
quest for better drugs and treatment schemes for MDR-TB, it is also essential to 
pay attention to factors beyond the interaction microbe-drug, to improve the 
beneficial impact of new developments in the treatment of these patients and the 
future of MDR-TB control. 
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Table 1. Demographics, clinical characteristics, and treatment outcomes of 128 patients with 
multidrug-resistant tuberculosis  
 
Characteristics 
Patients 
n (%) 
 
Total 
 
128 
Male  88 (69) 
Age, years, median (range) 40 (16-80) 
Time of treatment in months, median (range) 18 (1-28)  
Time of positive culture in months, median (range) 1 (1-10) 
Irregular treatment 
    Yes 
 
51 (40) 
No 77 (60) 
Risk factors for MDR-TB  
Yes † 112 (88) 
No 16 (12) 
Thoracic Surgery  
Yes 8 (6) 
No 120 (94) 
Co-morbidities  
HIV 14 (11) 
Diabetes 16 (13) 
Drug addiction 18 (14) 
COPD 10 (8) 
Undernourished 10 (8) 
Other 16 (13) 
Patient outcome  
Successful outcome 77 (60) 
The lost to follow up   26 (20) 
     Failure * 10 (8) 
     Dead 15 (12) 
  
 
† The risk factors were irregular prior anti-tuberculosis treatment or regular prior anti-tuberculosis 
treatment and contact with a TB patient. 
*Five patients died while receiving treatment.  
MDR-TB: Multidrug-resistant tuberculosis 
HIV: Human immunodeficiency virus  
COPD: Chronic obstructive pulmonary disease  
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Table 2. Characteristics of 128 patients with multidrug-resistant tuberculosis and 
their association with treatment outcomes 
 
Variable 
Poor 
outcome 
(n=51) 
Successful 
outcome 
(n=77)  
Univariate Multivariate 
OR (IC 95%) p OR (IC 95%) p 
Age (years)* 41 (15) 40 (14) 1.00 (0.98-1.02) 0.737 -  
Sex (male)†  33 (65) 55 (71) 0.73 (0.34-1.56) 0.422 -  
Irregular treatment† 32 (63) 19 (25) 5.14 (2.38-11.1) >0.001* 9.38 (2.30-38.2) 0.002* 
Time of treatment 
(months)* 
5 (12) 18 (2) 0.79 (0.73-0.85) >0.001* 0.66 (0.57-0.77) >0.001* 
Risk factor of MDR† 46 (90) 66 (86) 1.53 (0.49-4.70) 0.455 -  
Co-morbidities† 35 (69) 27 (35) 4.05 (1.90-8.61) >0.001* 2.33 (0.88-5.65)          0.089 
HIV† 10 (20) 4 (5) 4.45 (1.31-15.1) 0.017*       3.26           
(0.77-13.78)          
0.108 
Diabetes† 7 (14) 9 (12) 1.20 (0.41-3.46) 0.733 -  
Drug addiction† 13 (25) 5 (6) 4.92 (1.63-14.8) 0.005* 1.56 (0.42-5.73)          0.089 
COPD† 2 (4) 8 (10) 0.35 (0.07-1.73) 0.199 -  
Undernourished† 6 (12) 4 (5) 2.43 (0.65-9.09) 0.186 -  
Thoracic Surgery† 2 (4) 6 (8) 0.48 (0.09-2.49) 0.385 -  
Time of positive culture 
(months)* 
2 (3) 1 (1) 1.26 (1.02-1.56) 0.026* 1.85 (1.29-2.64) 0.001* 
 
[*] median (interquartile range); [†] Number (%). 
(OR) Odds Ratio, (CI) 95% confidence interval, (**) statistically significant 
differences (p< 0.05). 
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Figure 1. Flow chart of analyzed patients with MDR-TB. 
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Figure 2. Multiple correspondence analyses between treatment outcomes and 
patient’s base line conditions 
Based on the patient’s baseline conditions the Multiple Correspondence Analysis 
(MCA) shows several patterns: (a) Lost of follow-up was associated with HIV 
infection and drug addiction. (b) Dead and treatment failure were associated with 
patients with irregular treatment and COPD. (c) Diabetes and undernourished were 
not directly associated with any of the outcome categories defined in this study. (d) 
The successful outcome was not associated with any of the patient’s baseline 
conditions described in this study. The horizontal and vertical axes represent the 
first and second principal components. 
 
 
 
